Agitation associated with Alzheimer disease carries clinical challenges, and Auvelity's approval can reshape treatment selection, safety monitoring, and the pharmacist's role.
Robert Leffler, RPh, BCGP, FASCP
Advertisement
Articles by Robert Leffler, RPh, BCGP, FASCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
2
Building the pharmacy of the future — trust, loyalty, and growth
3
Beyond the Transplant Center: IV Therapy in the Community
4
Understanding Axatilimab's Mechanism in the Context of Multiple Lines of Therapy
5